DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Verslype C, Cohn A, Kelley R et al.
Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT).
J Clin Oncol 2012;
30 (suppl) 240s abstr 4007
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.